2012
Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes
Hanker LC, Rody A, Holtrich U, Pusztai L, Ruckhaeberle E, Liedtke C, Ahr A, Heinrich TM, Sänger N, Becker S, Karn T. Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes. Breast Cancer Research And Treatment 2012, 137: 407-416. PMID: 23242614, DOI: 10.1007/s10549-012-2356-2.Peer-Reviewed Original ResearchMeSH KeywordsB-LymphocytesBreast NeoplasmsDisease-Free SurvivalFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInterleukin-8Middle AgedOligonucleotide Array Sequence AnalysisPredictive Value of TestsPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneConceptsTriple-negative breast cancerCell/ILNegative breast cancerBreast cancer subtypesPrognostic valueBreast cancerBetter prognosisB cellsCancer subtypesIntrinsic breast cancer subtypesPrimary breast cancer samplesER-negative subtypesEvent-free survivalB cell signaturesHigher B cellsSignificant prognostic valueTriple-negative samplesBreast cancer samplesRoutine clinicopathological variablesOnly significant predictorSubtype-specific analysesTNBC subtypesClinicopathological variablesOutcome predictorsPrognostic evaluation
2011
A clinically relevant gene signature in triple negative and basal-like breast cancer
Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Müller V, Holtrich U, Kaufmann M. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Research 2011, 13: r97. PMID: 21978456, PMCID: PMC3262210, DOI: 10.1186/bcr3035.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBasal-like triple-negative breast cancerBreast cancerPrognostic markerMolecular subtypesMultivariate analysisBasal-like molecular subtypeClaudin-low molecular subtypeBasal-like breast cancerAttractive novel therapeutic targetB cell presenceHigh expressionER-positive cancersHigh histological gradeHigher B cellsIL-8 pathwayIL-8 activityNegative breast cancerNew prognostic markerNovel therapeutic targetBiology-based therapiesNon-neoplastic cell populationsRelevant gene signaturesRoutine clinicopathological variablesResultsSeventy-three percent
2010
Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular Anatomy of Breast Cancer Stroma and Its Prognostic Value in Estrogen Receptor–Positive and –Negative Cancers. Journal Of Clinical Oncology 2010, 28: 4316-4323. PMID: 20805453, DOI: 10.1200/jco.2009.27.2419.Peer-Reviewed Original ResearchMeSH KeywordsAmyloid beta-Protein PrecursorAntineoplastic Agents, HormonalBiopsy, Fine-NeedleB-LymphocytesBreast NeoplasmsChi-Square DistributionCollagen Type IVExtracellular Matrix ProteinsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMetagenomeNeoplasm Recurrence, LocalPhospholipid Transfer ProteinsPrognosisProportional Hazards ModelsProspective StudiesProtease NexinsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Cell SurfaceReceptors, EstrogenReceptors, Transforming Growth Factor betaSurvival AnalysisTamoxifenConceptsER-negative cancersBreast cancer stromaER-positive cancersPrognostic valueCancer stromaNegative cancersProliferative cancersSystemic adjuvant therapyTamoxifen-treated patientsNode-negative patientsEstrogen-receptor positiveStrong prognostic valueCore needle biopsySubset of tumorsLess prognostic valueDistant relapseAdjuvant therapyHazard ratioFavorable prognosisHighest tertilePrognostic scoreCore biopsyBreast cancerImmune functionMultivariate analysis